[go: up one dir, main page]

BE2016C024I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C024I2
BE2016C024I2 BE2016C024C BE2016C024C BE2016C024I2 BE 2016C024 I2 BE2016C024 I2 BE 2016C024I2 BE 2016C024 C BE2016C024 C BE 2016C024C BE 2016C024 C BE2016C024 C BE 2016C024C BE 2016C024 I2 BE2016C024 I2 BE 2016C024I2
Authority
BE
Belgium
Prior art keywords
factor viii
inhibitory antibodies
amino acid
modified factor
loci
Prior art date
Application number
BE2016C024C
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BE2016C024I2 publication Critical patent/BE2016C024I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
BE2016C024C 2000-03-10 2016-05-02 BE2016C024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (fr) 2000-03-10 2001-02-16 Facteur viii modifie

Publications (1)

Publication Number Publication Date
BE2016C024I2 true BE2016C024I2 (fr) 2020-01-30

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C024C BE2016C024I2 (fr) 2000-03-10 2016-05-02

Country Status (35)

Country Link
US (3) US6458563B1 (fr)
EP (1) EP1280540B1 (fr)
JP (1) JP4044337B2 (fr)
KR (1) KR100485525B1 (fr)
CN (1) CN1191360C (fr)
AT (1) ATE391512T1 (fr)
AU (2) AU2001238416B2 (fr)
BE (1) BE2016C024I2 (fr)
BR (2) BR122013026957A8 (fr)
CA (1) CA2400295C (fr)
CY (2) CY1108179T1 (fr)
CZ (1) CZ298250B6 (fr)
DE (1) DE60133541T2 (fr)
DK (1) DK1280540T3 (fr)
EE (1) EE05075B1 (fr)
ES (1) ES2304379T3 (fr)
FR (1) FR16C0016I2 (fr)
HU (2) HU227804B1 (fr)
IL (2) IL151371A0 (fr)
LT (1) LTC1280540I2 (fr)
LU (1) LU93049I2 (fr)
ME (1) MEP8209A (fr)
MX (1) MXPA02008798A (fr)
NL (1) NL300808I2 (fr)
NO (2) NO331935B1 (fr)
NZ (1) NZ520799A (fr)
PL (1) PL202936B1 (fr)
PT (1) PT1280540E (fr)
RS (1) RS50364B (fr)
RU (1) RU2285724C2 (fr)
SI (1) SI1280540T1 (fr)
SK (1) SK286205B6 (fr)
UA (1) UA75064C2 (fr)
WO (1) WO2001068109A1 (fr)
ZA (1) ZA200206810B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
JP4634036B2 (ja) * 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2526120A1 (fr) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
PL1636261T3 (pl) * 2003-06-26 2007-12-31 Merck Patent Gmbh Białka trombopoetynowe o ulepszonych właściwościach
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
PT1750733E (pt) * 2004-05-03 2014-02-14 Baxter Healthcare Sa Método de administração de factor viii suíno sem domínio b
WO2005123928A1 (fr) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production du facteur viii de coagulation humain à partir de cellules végétales et de plantes entières
HRP20070268B1 (hr) * 2004-11-12 2018-04-20 Bayer Healthcare Llc Ciljana modifikacija faktora viii
WO2006063031A2 (fr) * 2004-12-06 2006-06-15 Haplomics Variants alleliques du facteur viii humain
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2632714A1 (fr) 2005-12-07 2007-06-14 Technische Universitaet Muenchen Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP2097096B1 (fr) * 2006-12-22 2017-05-31 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
EP1935430A1 (fr) * 2006-12-22 2008-06-25 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (fr) 2007-05-04 2008-11-05 Novo Nordisk A/S Amélioration des titres de polypeptide de facteur VIII dans les cultures cellulaires
MX2010004813A (es) * 2007-11-01 2010-10-04 Univ Rochester Factor viii recombinante que tiene estabilidad incrementada.
EP2149603A1 (fr) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
WO2011060372A2 (fr) * 2009-11-13 2011-05-19 Puget Sound Blood Center Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
PT3326643T (pt) 2009-12-06 2021-07-12 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de fator viii-fc e métodos para a sua utilização
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012006623A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systèmes pour le traitement du facteur viii et procédés associés
DK2635297T3 (da) * 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
KR20140036144A (ko) * 2011-01-05 2014-03-25 익스프레션 테라퍼틱스 엘엘씨 고수율 현탁세포주, 시스템 및 그 제조방법
CA2838833A1 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composes pro-coagulants et leurs procedes d'utilisation
EP3513804B1 (fr) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Polypeptides chimériques et hybrides de facteur viii et leurs procédés d'utilisation
EP2737311B1 (fr) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Dosages pour la surveillance de troubles hémostatiques
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Facteurs de coagulation chimeriques
EP2870250B2 (fr) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (fr) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Procédés d'utilisation du polypeptide fviii
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
CN105392495A (zh) 2013-06-28 2016-03-09 比奥根Ma公司 具有xten的凝血酶可裂解连接子和其用途
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015059121A1 (fr) 2013-10-22 2015-04-30 Dbv Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (fr) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3107561A4 (fr) * 2014-02-19 2017-12-20 Bloodworks Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
WO2015132724A1 (fr) 2014-03-05 2015-09-11 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG10202106307UA (en) 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
KR102175878B1 (ko) 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3622065A1 (fr) 2017-05-09 2020-03-18 Emory University Variants du facteur de coagulation et leur utilisation
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
WO2019152692A1 (fr) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Utilisation de vecteurs lentiviraux exprimant le facteur viii
US12161760B2 (en) 2018-04-04 2024-12-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
MX2021000582A (es) 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
CA3108799A1 (fr) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Molecules d'acide nucleique et leurs utilisations pour une therapie genique non virale
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
WO2021067389A1 (fr) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Formulations de vecteur lentiviral
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
EP4171657A1 (fr) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Procédés pour retirer le facteur viii à l'état libre contenu dans des préparations de vecteurs lentiviraux modifiés pour exprimer ladite protéine
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
WO2022212162A1 (fr) * 2021-03-31 2022-10-06 Haemonetics Corporation Formulations de contrôle de qualité de dispositif de mesure d'hémostase
WO2022264040A1 (fr) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue
EP4392443A1 (fr) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Gènes de facteur viii optimisés
JP2024537797A (ja) 2021-09-30 2024-10-16 バイオベラティブ セラピューティクス インコーポレイテッド 低下した免疫原性を有する第ｖｉｉｉ因子ポリペプチドをコードする核酸
EP4602155A1 (fr) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (fr) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production de facteur VIII et produits apparentés
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
EP0737746A3 (fr) * 1989-12-01 1996-10-23 Pharming B.V. Production de polypeptides recombinants par l'espèce bovine et procédés transgéniques
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
KR100638184B1 (ko) * 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
EP1280540B1 (fr) 2008-04-09
NO2016007I1 (no) 2016-05-10
CN1416348A (zh) 2003-05-07
LU93049I2 (fr) 2016-06-27
KR20020081426A (ko) 2002-10-26
EP1280540A1 (fr) 2003-02-05
NL300808I2 (nl) 2020-12-21
AU3841601A (en) 2001-09-24
NO2016007I2 (no) 2016-05-10
CY2016011I2 (el) 2016-10-05
JP2003526358A (ja) 2003-09-09
MXPA02008798A (es) 2003-04-25
CA2400295A1 (fr) 2001-09-20
LTC1280540I2 (lt) 2020-05-25
NL300808I1 (fr) 2016-05-18
DE60133541T2 (de) 2009-05-07
SK286205B6 (sk) 2008-05-06
BR0109131A (pt) 2004-12-07
DK1280540T3 (da) 2008-07-14
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
HUP0300586A3 (en) 2006-11-28
NO331935B1 (no) 2012-05-07
PT1280540E (pt) 2008-06-09
JP4044337B2 (ja) 2008-02-06
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
CN1191360C (zh) 2005-03-02
HUS1600020I1 (hu) 2016-06-28
FR16C0016I1 (fr) 2016-04-29
BR122013026957A2 (fr) 2004-12-07
BRPI0109131B1 (pt) 2020-08-25
BRPI0109131B8 (pt) 2021-07-06
CZ20023346A3 (cs) 2003-01-15
RU2002124123A (ru) 2004-03-27
EE200200510A (et) 2004-02-16
BR122013026957A8 (pt) 2017-02-21
HK1051004A1 (en) 2003-07-18
EP1280540A4 (fr) 2004-11-03
UA75064C2 (en) 2006-03-15
CY2016011I1 (el) 2016-10-05
SI1280540T1 (sl) 2008-08-31
NO20024296L (no) 2002-11-08
RS50364B (sr) 2009-11-10
AU2001238416B2 (en) 2004-09-02
DE60133541D1 (de) 2008-05-21
US6458563B1 (en) 2002-10-01
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
IL151371A (en) 2010-12-30
HUP0300586A2 (hu) 2003-06-28
PL359672A1 (en) 2004-09-06
US7122634B2 (en) 2006-10-17
IL151371A0 (en) 2003-04-10
ME00601B (fr) 2011-12-20
SK14392002A3 (sk) 2003-06-03
US20030068785A1 (en) 2003-04-10
CY1108179T1 (el) 2014-02-12
CA2400295C (fr) 2012-01-10
MEP8209A (en) 2011-12-20
US7012132B2 (en) 2006-03-14
YU68002A (sh) 2005-11-28
PL202936B1 (pl) 2009-08-31
CZ298250B6 (cs) 2007-08-01
KR100485525B1 (ko) 2005-04-28
WO2001068109A1 (fr) 2001-09-20
NZ520799A (en) 2004-06-25
ES2304379T3 (es) 2008-10-16
FR16C0016I2 (fr) 2018-11-02
ATE391512T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
NL300808I1 (fr)
PT1200105E (pt) Factor viii modificado
EP1194164B8 (fr) Peptides proteiniques du prion et utilisations associees
GB0225474D0 (en) Therapeutic agents
DK1200418T3 (da) Nematodicide trifluorbutener
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0108592D0 (en) Therapeutic agents
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
TR200200278T2 (tr) Kalsilitik bileşimler
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин